纽福斯（上海）生物科技有限公司 Mediaroom

Neurophth Announces Completion of Patient Enrollment for Opvika® Phase I/II Clinical Trial in the U.S.

WUHAN, China and SAN DIEGO, Feb. 19, 2024 /PRNewswire/ -- Neurophth Therapeutics, Inc. ("Neurophth"...

2024-02-19 19:30 1506

Neurophth Announces First Patient Dosed in Phase I/II Clinical Trial of Second Gene Therapy

WUHAN, China and SAN DIEGO, Aug. 17, 2023 /PRNewswire/ -- Neurophth Therapeutics, Inc. ("Neurophth"...

2023-08-17 21:00 1447

Neurophth Secures Nearly 95 Million USD in Series C+ Financing for Gene Therapy Clinical Trials

WUHAN, China and SAN DIEGO, Aug. 11, 2023 /PRNewswire/ -- Neurophth Therapeutics, Inc. ("Neurophth"...

2023-08-11 21:00 2616

Commercialization of Gene Therapy is coming soon: Neurophth Completes Patient Enrollment for Phase III clinical trial for the gene therapy treatment of LHON

WUHAN, China and SAN DIEGO, Feb. 21, 2023 /PRNewswire/ -- Neurophth Therapeutics, Inc. ("Neurophth"...

2023-02-21 21:30 2618

Neurophth Receives IND Clearance from FDA for AAV-ND1 Gene Therapy of LHON

WUHAN, China and SAN DIEGO, Dec. 19, 2022 /PRNewswire/ -- Neurophth Therapeutics, Inc. ("Neurophth"...

2022-12-19 21:00 1822

Neurophth Therapeutics Conducts Special Interview with Dr. Satoshi Kashii on World Sight Day

WUHAN, China and SAN DIEGO, Calif., Oct. 13, 2022 /PRNewswire/ -- October 13th is World Sight Day.T...

2022-10-13 20:30 2128

Neurophth Therapeutics Conducts Special Interview with Dr. Satoshi Kashii on World Sight Day

Neurophth announces first patient dosed in Phase III clinical trial for the gene therapy treatment of LHON

WUHAN, China and SAN DIEGO, Sept. 27, 2022 /PRNewswire/ -- Neurophth Therapeutics, Inc. ("Neurophth...

2022-09-27 20:30 1344

Special interview with Dr. Patrick Yu-Wai-Man on International LHON Awareness Day

WUHAN, China and SAN DIEGO, Sept. 19, 2022 /PRNewswire/ -- September 19th is International LHON Awa...

2022-09-19 20:00 2384

Special interview with Dr. Patrick Yu-Wai-Man on International LHON Awareness Day

China CDE Grants Breakthrough Therapy Designation (BTD) to Neurophth's NR082 in LHON

WUHAN, China and SAN DIEGO, July 15, 2022 /PRNewswire/ -- Neurophth Therapeutics, Inc., ("Neurophth...

2022-07-15 21:00 5002

The 3rd BIO International Convention 2022 is Approaching

SAN DIEGO, June 7, 2022 /PRNewswire/ -- With the 3rd BIO International Convention 2022 soon approac...

2022-06-07 19:23 1712

The 3rd BIO International Convention 2022 is Approaching

Neurophth Therapeutics Appoints Xiaoning Guo as Chief Medical Officer

SHANGHAI and SAN DIEGO, June 2, 2022 /PRNewswire/ -- Neurophth Therapeutics, Inc., (hereinafter ref...

2022-06-02 21:00 2540

Neurophth Therapeutics Appoints Xiaoning Guo as Chief Medical Officer

Neurophth Therapeutics' Treatment of Leber's Hereditary Optic Neuropathy Gene Therapy NR082 was Granted Orphan Drug Designation by EMA

WUHAN, China and SAN DIEGO, Jan. 25, 2022 /PRNewswire/ -- Neurophth Therapeutics, Inc., (hereinafte...

2022-01-25 22:00 1621

Neurophth Therapeutics Receives IND Clearance to Initiate Clinical Trial for China AAV-ND4 Gene Therapy NR082 in Leber Hereditary Optic Neuropathy

WUHAN, China and SAN DIEGO, Jan. 19, 2022 /PRNewswire/ -- Neurophth Therapeutics, Inc., (hereinafte...

2022-01-19 22:30 1803

Neurophth Therapeutics Strengthens Leadership Team with Appointment of Su Zhang as Chief Financial Officer

SHANGHAI and SAN DIEGO, Nov. 24, 2021 /PRNewswire/ -- Neurophth Biotechnology Ltd., a fully-integra...

2021-11-24 21:30 1910

Neurophth Raised Over $60 Million USD in Series-C Financing to Advance Gene Therapies

SAN DIEGO, Nov. 23, 2021 /PRNewswire/ -- Neurophth Therapeutics Ltd., ("Neurophth"), a fully integr...

2021-11-23 21:30 1591

Neurophth Raised Over $60 Million USD in Series-C Financing to Advance Gene Therapies

Neurophth Announces the Completion of GMP Manufacturing Facility for Gene Therapy Products According to International Standards

WUHAN, China and SAN DIEGO, Sept. 27, 2021 /PRNewswire/ -- Neurophth Biotechnology Ltd., a fully-in...

2021-09-27 23:00 1689

Neurophth Announces the Completion of GMP Manufacturing Facility for Gene Therapy Products According to International Standards

Neurophth Expands Its Global Gene Therapy Leadership Team with the Appointment of Dr. Zhengbin Li as Head of Commercial

WUHAN, China and SAN DIEGO, Aug. 19, 2021 /PRNewswire/ -- Neurophth Biotechnology Ltd., a fully-int...

2021-08-19 22:00 1645

First in China! Neurophth announced the first patient has been dosed in G.O.L.D. clinical trial for the gene therapy treatment of LHON

* Novel and one-time intravitreal injection of ND4 gene therapy for the treatment of LHON potenti...

2021-06-28 21:33 1618

Neurophth Therapeutics and Hopstem Biotechnology Announce Strategic Partnership to Develop Human Induced Pluripotent Stem Cell-Derived Therapies for the Treatment of Ocular Diseases

HOUSTON and SAN DIEGO, June 1, 2021 /PRNewswire/ -- Neurophth Biotechnology Ltd., a fully-integrate...

2021-06-01 19:50 1196

Neurophth Announces IND Approval by the NMPA for Leber Hereditary Optic Neuropathy Gene Therapy

WUHAN and SUZHOU, China, April 1, 2021 /PRNewswire/ -- Neurophth Biotechnology Ltd., a fully-integr...

2021-04-01 20:39 5105

Latest News